Literature DB >> 14615052

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Henrik Zetterberg1, Lars-Olof Wahlund, Kaj Blennow.   

Abstract

A major diagnostic challenge when people seek advice for cognitive dysfunction is to differentiate between mild cognitive impairment (MCI) and incipient Alzheimer's disease (AD). We show that a combination of three cerebrospinal fluid biochemical markers, total-tau, phospho-tau and beta-amyloid(1-42), can detect incipient AD among patients fulfilling the criteria for MCI with a sensitivity of 68% (95% CI 45-86%) and a specificity of 97% (95% CI 83-100%). The usefulness of these markers is further emphasized by the finding of a positive predictive value of 94% and a negative predictive value of 81%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615052     DOI: 10.1016/j.neulet.2003.08.011

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  46 in total

Review 1.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

Review 2.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

3.  Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease.

Authors:  Joana R F Santos; Chris Bauer; Johannes Schuchhardt; Dirk Wedekind; Katharina Waniek; Ingolf Lachmann; Jens Wiltfang; Jonathan Vogelgsang
Journal:  J Neural Transm (Vienna)       Date:  2019-02-14       Impact factor: 3.575

Review 4.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

Review 5.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

6.  Association of the RAGE G82S polymorphism with Alzheimer's disease.

Authors:  Jonny Daborg; Malin von Otter; Annica Sjölander; Staffan Nilsson; Lennart Minthon; Deborah R Gustafson; Ingmar Skoog; Kaj Blennow; Henrik Zetterberg
Journal:  J Neural Transm (Vienna)       Date:  2010-06-22       Impact factor: 3.575

7.  Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Authors:  Niklas Mattsson; Henrik Zetterberg; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-08

8.  Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Authors:  Mi-Ryung Han; Gerard D Schellenberg; Li-San Wang
Journal:  BMC Neurol       Date:  2010-10-08       Impact factor: 2.474

9.  Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures.

Authors:  W J P Henneman; J D Sluimer; J Barnes; W M van der Flier; I C Sluimer; N C Fox; P Scheltens; H Vrenken; F Barkhof
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

Review 10.  Protein-based biomarkers in cerebrospinal fluid and blood for Alzheimer's disease.

Authors:  Yongyao Fu; Deming Zhao; Lifeng Yang
Journal:  J Mol Neurosci       Date:  2014-06-25       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.